141 related articles for article (PubMed ID: 38640408)
1. About the Editor: Neda Laiteerapong, MD, MS: Using Economic Modeling to Improve Access to Care.
Page B
Diabetes Care; 2024 May; 47(5):766-767. PubMed ID: 38640408
[No Abstract] [Full Text] [Related]
2. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
3. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
[TBL] [Abstract][Full Text] [Related]
4. "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?
Mayssam EN; Eid C; Khoury SJ; Hannoun S
Mult Scler Relat Disord; 2020 May; 40():101935. PubMed ID: 31951861
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
6. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Collura F; Bazzurri V; Fiore A; Granella F
J Neurol Sci; 2020 Jul; 414():116827. PubMed ID: 32289575
[TBL] [Abstract][Full Text] [Related]
7. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
[TBL] [Abstract][Full Text] [Related]
8. The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
Di Sabatino E; Gaetani L; Sperandei S; Fiacca A; Guercini G; Parnetti L; Di Filippo M
J Neurol; 2022 Jun; 269(6):3129-3135. PubMed ID: 34820734
[TBL] [Abstract][Full Text] [Related]
9. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
Szilasiová J; Rosenberger J; Fedičová M; Mikula P; Urban P; Gdovinová Z; Vitková M; Hanes J; Stevens E
Eur Neurol; 2021; 84(4):272-279. PubMed ID: 34034261
[TBL] [Abstract][Full Text] [Related]
10. The evolution of "No Evidence of Disease Activity" in multiple sclerosis.
Lu G; Beadnall HN; Barton J; Hardy TA; Wang C; Barnett MH
Mult Scler Relat Disord; 2018 Feb; 20():231-238. PubMed ID: 29579629
[TBL] [Abstract][Full Text] [Related]
11. No evidence of disease activity in multiple sclerosis patients.
Matta AP; Nascimento OJ; Ferreira AC; Magalhães TN; Benevides TP; Kirmse A; Dib JG; Cal H; Orsini M; Araujo LM
Expert Rev Neurother; 2016 Nov; 16(11):1279-1284. PubMed ID: 27352830
[TBL] [Abstract][Full Text] [Related]
12. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
[TBL] [Abstract][Full Text] [Related]
13. Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
Rotstein D; Solomon JM; Sormani MP; Montalban X; Ye XY; Dababneh D; Muccilli A; Shah P
Neurology; 2022 Jul; 99(2):e209-e220. PubMed ID: 35473761
[TBL] [Abstract][Full Text] [Related]
14. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
15. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
16. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
Newsome SD; Binns C; Kaunzner UW; Morgan S; Halper J
Neurol Ther; 2023 Dec; 12(6):1909-1935. PubMed ID: 37819598
[TBL] [Abstract][Full Text] [Related]
17. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
[TBL] [Abstract][Full Text] [Related]
18. Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis.
Fedičová M; Mikula P; Gdovinová Z; Vitková M; Žilka N; Hanes J; Frigová L; Szilasiová J
Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241097
[No Abstract] [Full Text] [Related]
19. Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.
Monschein T; Salhofer-Polanyi S; Altmann P; Zrzavy T; Dal-Bianco A; Bsteh G; Rommer P; Berger T; Leutmezer F
J Neurol; 2021 Apr; 268(4):1247-1253. PubMed ID: 32929591
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer L; Galetta S; Campagnolo DI; Avila R; Lee L; Rutledge D; Fox RJ
Adv Ther; 2021 Jul; 38(7):3724-3742. PubMed ID: 34014549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
